As to PPARγ agonists, although clinical trials for rosiglitazone in patients with type 2 diabetes reported improvement of steatosis by a median of 20% during the first year, no further improvement was found after 2 additional years of treatment, and the trials exposed severe cardiovascular risks and weight gain [43]. Here, PPARG is linked to type 2 diabetes mellitus.